演題詳細

ポスター / Poster

ポスター 10 (Poster 10) :CML:臨床 2

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
増子 正義 (Masayoshi Masuko):1
1:新潟大学医歯学総合病院 高密度無菌治療部
 
前へ戻る

Treatment with nilotinib and rituximab in a CML patient developed non-Hodgkin lymphoma

演題番号 : PS-1-70

下山 学 (Manabu Shimoyama):1、森田 倫世 (Tomoyo Morita):2、上田 佳世 (Kayo Ueda):3、寺村 一裕 (Kazuhiro Teramura):3、岩田 暢子 (Nobuko Iwata):1

1:Dept. of Hematology, Yodogawa Christian Hospital, Osaka, Japan、2:Dept. of Respiratory Medicine, Yodogawa Christian Hospital, Osaka, Japan、3:Dept. of Pathology, Yodogawa Christian Hospital, Osaka, Japan

 

A 92-years old female who treated with nilotinib for CML visited our hospital complaining of dyspnea. Chest X-ray showed right pleural effusion. Malignant cells in the pleural fluid were identified by cytorogy. It was difficult to determine whether the neoplastic cells were derived from CML blast crisis or other hematological malignancies based on morphology. These cells expressed CD19 and CD20, and they were lambda light chain dominant by flow cytometry. The bcr/abl fusion gene signal was not detected using metaphase FISH. Thus we concluded that B-cell lymphoma developed in the course of CML. She was administered retuximab and etoposide in addition to nilotinib treatment. Adjunction of retuximab to nilotinib revealed no special toxicity. Pleural effusion decreased and she remains in complete cytogenetic response of CML.

前へ戻る